It is recommended to monitor liver function before treatment, after 1 month after it began, and then every 3 months. It should also determine the level of lipids in the serum of fasting (before treatment, after 1 month after the beginning and the end of the 3-4-month course of treatment).
In rare cases, patients receiving Roaccutane, described depression, psychotic symptoms and suicidal attempts. Although their causal connection with the use of the drug is not installed, you must be especially cautious in patients with a history of depression and monitor all patients for depression during treatment with medication, if necessary, directing them to the appropriate specialist.
Because of the possibility of bone changes need to appoint Roaccutane only in severe forms of the disease, carefully evaluating the ratio of potential benefits and risks, and limiting the use of the drug only severe cases.
Since acne is androgen-dependent diseases, do not use contraceptives containing a progestin with androgenic effect, such as derivatives of 19-nortestosterona, especially if the patient has a gynecological endocrine pathology.
Should be avoided dermoabrazii patients receiving Roaccutane, as well as within 5-6 months after treatment because of the possibility of enhanced healing in atypical locations.
In the course of treatment Roaccutane and within 5-6 months after it could not hold hair removal with wax applications because of the risk of dermatitis.
Patients at high risk (with diabetes, obesity, alcoholism or problems with fat metabolism) in the treatment Roaccutane may require more frequent laboratory monitoring of relevant indicators.
If you have diabetes or suspected, it is recommended more frequent determination of blood glucose. There are reports of increasing levels of fasting blood glucose and cases of diabetes during treatment Roaccutane, although their causal relationship to drug intake is not installed.
Patients who are receiving or shortly before (1-2 weeks) received Roaccutane, you can not take the donated blood for transfusion to women of childbearing age.
